Vaginal and Oral Interventions to Control the Epidemic – tested the safety and effectiveness of two different HIV prevention approaches among 5,029 women in Uganda, South Africa and Zimbabwe: daily use of an antiretroviral (ARV) tablet (tenofovir or Truvada) or daily use of a vaginal gel (tenofovir gel). The first set of results, reported in March 2013, found none of the products effective; most participants did not use them daily as recommended. Young, unmarried women were least likely to use study product and the most likely to acquire HIV, indicating the urgent need for safe, effective and practical HIV prevention methods women like those in VOICE will actually use. Results of two qualitative behavioral sub-studies, VOICE C and VOICE D, should help to better understand the reasons why so many women did not use the products in VOICE.
VOICE also included three sub-studies: VOICE B (Bone Mineral Density), VOICE C (Household and Community Factors Associated with Adherence), and VOICE D, which is looking to better understand women’s actual use of study products and sexual behavior during their participation in VOICE, and in particular to understand why women enrolled and remained in VOICE yet so few adhered to product use. While VOICE B and C have been completed, results are not yet available. VOICE D is ongoing with results expected in 2015.
Please note that the information contained in the following materials may have changed since publication.